PEGylated cholecystokinin is more potent in inducing anorexia than conditioned taste aversion in rats.
OBJECTIVE
The physiological involvement of endogenous cholecystokinin (CCK) in the termination of feeding has been challenged by evidence of aversive effects of exogenous CCK8. We previously prolonged the anorectic effect of CCK by conjugation to polyethylene glycol (PEGylation) to produce PEG-CCK9. In this study, we investigated the ability of different doses of PEG-CCK9 to induce conditioned taste aversion (CTA) and satiety and identified the receptors involved in CTA induction.


METHODS
Induction of CTA, measured by the saccharin preference ratio determined in a two-bottle CTA procedure, and of satiety in adult male Wistar rats after intraperitoneal (i.p.) injection of different doses of PEG-CCK9 (1, 2, 4, 8, 16 or 32 microg kg(-1)) was compared. Devazepide (100 microg kg(-1)) and 2-NAP (3 mg kg(-1)), two selective CCK1-receptor antagonists, were co-administered i.p. with PEG-CCK9 (8 microg kg(-1)) and the CTA effects monitored.


RESULTS
PEG-CCK9 dose-dependently induced CTA, with a minimal effective dose of 8 microg kg(-1), whereas the minimal effective dose to induce satiety was 1 microg kg(-1). The CTA effects of PEG-CCK9 were completely abolished by i.p. administration of devazepide prior to PEG-CCK9 treatment and only partially abolished by administration of 2-NAP.


CONCLUSIONS
Although PEG-CCK9-induced satiety and PEG-CCK9-induced CTA both increased with dose, the conjugate was more potent in inducing satiety, suggesting that the anorexia could not be completely attributed to the aversiveness of the drug. As observed with induction of satiety, PEG-CCK9-induced CTA was mediated by CCK1-receptors.
Verbaeys
I
I
Interdisciplinary Research Center, Katholieke Universiteit Leuven, Campus Kortrijk, Kortrijk, Belgium.
León-Tamariz
F
F
Pottel
H
H
Decuypere
E
E
Swennen
Q
Q
Cokelaere
M
M
D000818:Animals; D000855:Anorexia / Q000139:chemically induced*; D001224:Aspartic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D001362:Avoidance Learning / Q000187:drug effects; D002766:Cholecystokinin / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D020109:Devazepide / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D007274:Injections, Intraperitoneal; D008297:Male; D009282:Naphthalenesulfonates / Q000494:pharmacology; D010446:Peptide Fragments / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D011092:Polyethylene Glycols / Q000737:chemistry; D051381:Rats; D017208:Rats, Wistar; D043886:Receptor, Cholecystokinin A / Q000187:drug effects* / Q000378:metabolism; D012439:Saccharin; D012528:Satiety Response / Q000187:drug effects*; D013649:Taste
D009282:Naphthalenesulfonates; D010446:Peptide Fragments; D043886:Receptor, Cholecystokinin A; C053399:cholecystokinin 9; C080661:N-(2-naphthalenesulfonyl)aspartyl-(2-phenethyl)amide; D001224:Aspartic Acid; D011092:Polyethylene Glycols; D002766:Cholecystokinin; D012439:Saccharin; D020109:Devazepide